Researchers at the University of Missouri have discovered a novel target for the treatment of pancreatic cancer. Using gene therapy they have demonstrated effective treatment of pancreatic cancer in animal models of this difficult to treat disease. This discovery promises to offer new therapeutic options where convention treatments often fail.
Pancreatic cancer is the fourth leading cause of cancer death in the US. Conventional cancer therapies such as chemotherapy and radiation are often ineffective, as pancreatic cancer is usually not detected until after it has metastasized. This leaves approximately 80% of pancreatic cancer patients with no options for effective treatment.
Inventors at the University of Missouri, have identified a novel target demonstrated to be effective at treating pancreatic cancer. In vivo mouse model data demonstrate effective 10x reduction of tumor load.
- Pancreatic cancer treatment (especially where chemotherapy and surgery fail)
- Potential application to other cancer types (to be tested)
- An alternative to chemotherapy, surgery, and other treatment options that are often ineffective
- Uses FDA-approved methods
- Novel target for treatment of pancreatic cancer
State of Development: Early stage, preclinical, translational studies are in progress
Owner: University of Missouri-Columbia
IP Protection Status: Pending Patent